Babesiosis

Table of Contents

1. Overview
2. Epidemiology
3. Pathophysiology
4. Etiology and Risk Factors
5. Clinical Presentation
6. Diagnosis
7. Treatment
8. Complications
9. Prognosis
10. Prevention
11. References
12. Research Papers
13. Connections
14. Featured Videos

1. Overview

Babesiosis is a tick-borne infection caused by intraerythrocytic protozoan parasites of the genus Babesia. These microscopic parasites invade and destroy red blood cells in a manner that closely resembles malaria, producing a hemolytic illness that ranges from completely asymptomatic to rapidly fatal. Unlike malaria, which is caused by Plasmodium species transmitted by mosquitoes, babesiosis is transmitted primarily by hard-bodied Ixodes ticks — the same tick vector responsible for Lyme disease and human granulocytic anaplasmosis.

In the United States, Babesia microti is the predominant species, circulating in the Northeast and Upper Midwest via the black-legged tick (Ixodes scapularis) with the white-footed mouse (Peromyscus leucopus) as the primary reservoir host. In Europe, Babesia divergens — a bovine parasite transmitted by Ixodes ricinus — causes a rarer but far more severe illness with high fatality in asplenic individuals. Globally, over 100 Babesia species infect a wide range of vertebrate hosts, but fewer than a dozen cause human disease.

A defining public health concern is transmission via blood transfusion: Babesia is the leading transfusion-transmitted parasitic infection in the United States, with over 250 transfusion-associated cases reported to the CDC and an estimated true burden many times higher. Asymptomatic donors in endemic areas may harbor parasitemia for months without knowing they are infected. The FDA issued guidance in 2019 and updated it in 2023 directing blood collection centers in 14 high-incidence states to test donations using approved NAT and antibody assays.

Back to Table of Contents

2. Epidemiology

United States: Babesiosis is a nationally notifiable disease since 2011. Approximately 2,000–3,000 cases are reported to the CDC annually, with a strong geographic concentration in New England (particularly Rhode Island, Connecticut, Massachusetts, and New York), the Upper Midwest (Wisconsin and Minnesota), and the Atlantic coastal islands (Nantucket, Martha's Vineyard, Block Island). Incidence has increased significantly since the 1980s as the range of I. scapularis has expanded northward and westward with changing climate and increasing deer populations.

Seasonality: Most cases occur from May through October, reflecting the peak activity of nymphal-stage I. scapularis ticks. Nymphs — smaller than a poppy seed — are the most efficient transmission stage because they are difficult to detect and remove promptly. Adult ticks are also capable of transmission but are larger and more easily noticed.

Reservoir ecology: The white-footed mouse (Peromyscus leucopus) is the primary reservoir for B. microti in the United States; it sustains long-lasting, high-level parasitemia without apparent illness. Other small mammals (chipmunks, voles, shrews) contribute to the enzootic cycle. White-tailed deer (Odocoileus virginianus) are essential hosts for adult I. scapularis ticks but do not themselves carry B. microti; deer overpopulation nonetheless amplifies tick abundance.

Europe: B. divergens infections occur sporadically across northern and western Europe; nearly all reported cases have involved asplenic individuals, in whom mortality without prompt treatment approaches 40–50%. B. microti cases are also reported in Europe, typically milder.

Blood transfusion: The CDC has recorded more than 250 confirmed transfusion-transmitted babesiosis cases since reporting began; an unknown additional number are misattributed to other causes. Risk is highest from donations made in spring and summer months from endemic regions.

Back to Table of Contents

3. Pathophysiology

Babesia sporozoites are injected into the bloodstream during tick feeding (minimum attachment time approximately 36–48 hours for B. microti). Sporozoites rapidly invade red blood cells by attaching to surface glycoproteins and initiating receptor-mediated endocytosis. Within the erythrocyte, the parasite undergoes asexual replication through budding rather than the schizogony seen in Plasmodium. The key intracellular forms are:

• Ring forms: Small, often multiple per cell (1–4), resembling early Plasmodium falciparum rings on Giemsa stain — but without the hemozoin (malaria pigment) that accumulates in older Plasmodium stages.
• Tetrad form ("Maltese cross"): Four daughter merozoites arranged in a cross-like tetrad within or budding from a single red cell — this finding is pathognomonic for Babesia and is not seen in malaria. It is most often found in B. microti infections on blood smear, though its sensitivity is low (found in only 1–20% of smears in mild infection).

Red cell lysis releases merozoites that reinvade neighboring erythrocytes, causing progressive hemolytic anemia. The severity of hemolysis correlates with the level of parasitemia. Unlike malaria, Babesia lacks a liver stage — there is no dormant hypnozoite form, and relapse occurs from persistent erythrocytic infection rather than hepatic reactivation.

The pathophysiologic consequences of red cell destruction include: hemolytic anemia with hemoglobinemia and hemoglobinuria; splenomegaly from accelerated erythrophagocytosis; thrombocytopenia from platelet consumption and sequestration; elevated liver transaminases from hepatic involvement and hemolysis; and in severe cases, acute kidney injury from hemoglobin cast nephropathy and cytokine-driven inflammation. The spleen plays a critical role in clearing parasitized red cells — asplenic individuals lose this filter entirely and can develop overwhelming parasitemia.

Back to Table of Contents

4. Etiology and Risk Factors

Causative species in humans:

• Babesia microti — most common US species; rodent reservoir; Ixodes scapularis tick; generally mild to moderate illness in immunocompetent adults.
• Babesia divergens — Europe; cattle reservoir; Ixodes ricinus tick; severe, often fatal in asplenic individuals.
• Babesia duncani (formerly WA1) — Pacific Coast (California, Oregon, Washington); reservoir uncertain; can cause severe illness.
• Babesia MO1, KO1, and others — rare case reports from Missouri, Korea, and other regions.

Routes of transmission:

• Tick bite (most common): Ixodes scapularis nymphal stage, May–October in Northeast and Upper Midwest.
• Blood transfusion: asymptomatic donors with low-level parasitemia; red cell products (not plasma or platelets carry lower risk but cases documented).
• Organ transplantation: rare case reports.
• Perinatal transmission: rare maternal-fetal transmission documented.

Risk factors for severe and life-threatening disease:

• Asplenia (surgical or functional, e.g., sickle cell disease) — single greatest risk factor; mortality can reach 20% or higher.
• Immunocompromising conditions: HIV/AIDS, cancer, organ transplantation, biologic therapies (rituximab especially).
• Age >50 years — even immunocompetent elderly individuals can develop severe disease.
• Corticosteroid use or other immunosuppressive medications.
• Co-infection with Lyme disease or ehrlichiosis — occurs in up to 20% of babesiosis cases in endemic areas and may worsen clinical course.
• Transfusion-associated babesiosis: immunocompromised and elderly recipients at highest risk for severe outcomes.

Back to Table of Contents

5. Clinical Presentation

Approximately 20–50% of adults and up to 40% of children infected with B. microti remain asymptomatic. In those who develop illness, the incubation period is 1–4 weeks after tick bite, or 1–9 weeks after transfusion.

Mild to moderate illness (most common in immunocompetent adults):

• Gradual onset of malaise, fatigue, and anorexia, followed by fever (often high, 38–40°C), chills, sweating, and myalgia.
• Headache, nausea, and vomiting are common; arthralgia and dark urine (from hemoglobinuria) may occur.
• Physical examination typically reveals fever and splenomegaly; hepatomegaly is less common; rash is absent (differentiating from Rocky Mountain spotted fever).
• Laboratory hallmarks: hemolytic anemia (falling hemoglobin, elevated LDH, low haptoglobin, elevated indirect bilirubin), thrombocytopenia, elevated AST/ALT, mildly elevated creatinine.

Severe illness (asplenic, immunocompromised, elderly, or high parasitemia):

• Rapidly progressive hemolysis with hemoglobin dropping to 5–7 g/dL or lower.
• Parasitemia levels exceeding 4–10% of red cells (in severe cases up to 85% in asplenic patients).
• Acute respiratory distress syndrome (ARDS) — non-cardiogenic pulmonary edema.
• Acute kidney injury from hemoglobin nephropathy and cytokine-mediated inflammation.
• Disseminated intravascular coagulation (DIC).
• Congestive heart failure and myocardial infarction in elderly patients.
• Altered mental status and coma in fulminant cases.

Co-infection: When babesiosis co-exists with Lyme disease or ehrlichiosis — which is common since all three share the same I. scapularis vector — patients tend to have more prolonged illness, more severe symptoms, and more frequent complications than those with a single infection.

Back to Table of Contents

6. Diagnosis

Peripheral blood smear (Giemsa or Wright stain): The cornerstone of diagnosis in acute illness with active parasitemia. Thin-film smear of peripheral blood is examined for intraerythrocytic ring forms. Key findings distinguishing Babesia from Plasmodium:

• Multiple ring forms per red cell (up to 4) — common in Babesia, rare in early P. falciparum only.
• Rings may appear at the periphery of the red cell or even extracellularly.
• Tetrad form ("Maltese cross"): Four merozoites joined in a cross or clover-leaf pattern within or budding from a single erythrocyte — pathognomonic for Babesia. Found on smear in approximately 1–20% of cases; its absence does not rule out infection.
• No hemozoin (malaria pigment) — the brown-black granular pigment present in older Plasmodium trophozoites and schizonts is absent in Babesia.
• Normal or enlarged red cell size (no enlarged schizont stage as in P. vivax or P. ovale).

PCR (polymerase chain reaction): More sensitive than blood smear, especially at low parasitemia levels. Real-time PCR targeting B. microti 18S rRNA is the preferred method when clinical suspicion is high but smear is negative. PCR also allows species identification, which is important for guiding therapy. FDA-approved NAT assays for blood donor screening target B. microti.

Serology (indirect immunofluorescence antibody, IFA): B. microti IgG and IgM can confirm exposure but may be negative early in illness. IgM peaks at 4 weeks; IgG may persist for months to years. Serology is useful for diagnosis of mild or resolving infection after parasitemia has cleared, and for transfusion-associated case investigations.

Complete blood count and chemistry: Hemolytic anemia (normocytic, elevated LDH, low haptoglobin), thrombocytopenia, elevated transaminases, and in severe cases elevated creatinine and bilirubin support the diagnosis.

Testing for co-infections: Always test for Lyme disease (Borrelia burgdorferi serology) and ehrlichiosis/anaplasmosis (PCR and serology) in patients with babesiosis from endemic areas, given the high rate of co-infection.

Back to Table of Contents

7. Treatment

Treatment is indicated for all symptomatic patients, regardless of the degree of parasitemia. Asymptomatic patients with persistent parasitemia detectable by PCR beyond 3 months may also be treated to prevent late complications.

Mild to Moderate Disease (most immunocompetent adults)

• Atovaquone 750 mg PO twice daily + Azithromycin 500 mg PO on day 1, then 250 mg daily × 7–10 days — first-line regimen; generally well tolerated; effective in most immunocompetent patients.
• Atovaquone inhibits the mitochondrial cytochrome bc1 complex in Babesia; azithromycin has anti-parasitic activity and acts synergistically. This combination is preferred over quinine + clindamycin in mild-moderate disease due to fewer adverse effects.

Severe Disease (high parasitemia, asplenic patients, immunocompromised)

• Quinine sulfate 650 mg PO three times daily + Clindamycin 600 mg IV or PO three times daily × 7–10 days — traditional first-line for severe disease; highly effective but poorly tolerated (quinine causes cinchonism: tinnitus, headache, nausea, and visual disturbances in up to 50% of patients).
• IV clindamycin (900 mg every 8 hours) for patients unable to tolerate oral medications or requiring hospitalization.
• Exchange transfusion: Indicated when parasitemia exceeds 10%, in the presence of severe hemolysis, ARDS, or multiorgan failure — rapidly reduces parasite burden, removes toxic hemolysis products, and replaces functioning red cells. Most patients undergoing exchange transfusion require 1–3 exchanges; combines with antiparasitic therapy.

Immunocompromised Patients

• Prolonged treatment courses of 6 weeks or more (with the last 2 weeks of PCR-confirmed parasite clearance) are recommended — immunocompromised patients, especially those on rituximab or with B-cell deficiencies, are at risk for relapsing babesiosis with drug-resistant Babesia.
• Atovaquone-azithromycin is preferred; azithromycin may be dose-escalated to 600–1000 mg/day in refractory cases.
• Consultation with an infectious disease specialist is essential for immunocompromised patients with babesiosis.

Back to Table of Contents

8. Complications

• Acute respiratory distress syndrome (ARDS): Non-cardiogenic pulmonary edema from cytokine-driven capillary leak; may require mechanical ventilation.
• Acute kidney injury: From hemoglobin nephropathy (cast formation) and direct cytokine effects; may progress to requiring renal replacement therapy.
• Disseminated intravascular coagulation (DIC): Consumptive coagulopathy with bleeding risk.
• Splenic rupture: Rare but catastrophic — splenomegaly from erythrophagocytosis can predispose to spontaneous or traumatic rupture.
• Myocardial infarction and congestive heart failure: In elderly patients with underlying coronary artery disease; profound anemia and increased cardiac demand from fever and hemolysis.
• Relapsing babesiosis: Particularly in B-cell-deficient patients (rituximab-treated lymphoma patients are especially vulnerable); may require prolonged or repeat treatment courses.
• Transfusion complications: Hemolytic reactions and TACO in elderly or cardiac-compromised patients receiving red cell transfusions for severe anemia.
• Death: Case fatality rates of 6–9% in hospitalized patients overall; 20% or higher in asplenic individuals and immunocompromised patients.

Back to Table of Contents

9. Prognosis

Immunocompetent adults: Prognosis is generally excellent with prompt diagnosis and appropriate antiparasitic therapy. Most patients defervesce within 48 hours of starting treatment and recover fully within 1–2 weeks. Fatigue may persist for weeks to months. Spontaneous resolution can occur in mild cases even without treatment, though this is not recommended given the risk of progression.

Asplenic and immunocompromised patients: These groups carry significantly higher mortality — 20% or more for asplenic individuals with B. microti and up to 40–50% for B. divergens in asplenic patients. Rapid recognition, early treatment with the appropriate regimen, and clinical vigilance for exchange transfusion indications are critical determinants of outcome.

Elderly patients: Even without predisposing conditions, adults over 70 years have higher rates of severe disease and hospitalization. The combination of reduced bone marrow reserve, underlying cardiovascular disease, and age-related immune senescence all contribute.

Relapsing disease: Immunocompromised patients — particularly those with depleted B cells from rituximab therapy — may experience multiple relapses requiring repeat or prolonged treatment. Drug resistance (atovaquone mutations) has been documented in treatment failure cases from these populations.

Back to Table of Contents

10. Prevention

Personal tick prevention (primary prevention):

• Use EPA-registered repellents: DEET (20–30%) on exposed skin; permethrin on clothing, boots, and gear (not skin).
• Wear light-colored long pants tucked into socks and long sleeves in tick-endemic areas, particularly during nymphal-peak season (May–July).
• Perform thorough tick checks within 2 hours of potential exposure; shower promptly after outdoor activities.
• Promptly remove any attached ticks with fine-tipped tweezers; grasp close to the skin and pull upward with steady even pressure. The risk of B. microti transmission requires tick attachment for approximately 36–48 hours — prompt removal prevents most transmission.
• Treat residential yard perimeters and leaf litter with acaricides (bifenthrin or other tick-control products) in endemic areas.

Blood supply safety: Since 2019, FDA guidance directs blood collection facilities in 14 high-incidence states to use approved NAT or antibody-based tests for Babesia in donated whole blood and red cell components. This has substantially reduced but not eliminated transfusion-transmitted cases. Patients who have had babesiosis should defer blood donation for at least 2 years and until they are PCR-negative.

High-risk individuals: Asplenic patients, immunocompromised individuals, and elderly persons living in or traveling to endemic regions should be counseled specifically about babesiosis risk and symptoms, and should seek prompt medical evaluation for any febrile illness in the weeks following potential tick exposure.

No vaccine against babesiosis currently exists for human use.

Back to Table of Contents

11. References

1. Vannier E, Krause PJ. Human babesiosis. N Engl J Med. 2012;366:2397–2407. PMID: 22716978. https://doi.org/10.1056/NEJMra1202000
2. Krause PJ, Gewurz BE, Hill D, et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis. 2008;46:370–376. PMID: 18181735. https://doi.org/10.1086/525852
3. Herwaldt BL, Linden JV, Bosserman E, et al. Transfusion-associated babesiosis in the United States: a description of cases. Ann Intern Med. 2011;155:509–519. PMID: 22007046. https://doi.org/10.7326/0003-4819-155-8-201110180-00362
4. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43:1089–1134. PMID: 17029130. https://doi.org/10.1086/508667
5. Krause PJ, Lepore T, Sikand VK, et al. Atovaquone and azithromycin for the treatment of babesiosis. N Engl J Med. 2000;343:1454–1458. PMID: 11078770. https://doi.org/10.1056/NEJM200011163432004
6. Vannier EG, Diuk-Wasser MA, Ben Mamoun C, Krause PJ. Babesiosis. Infect Dis Clin North Am. 2015;29:357–370. PMID: 25999229. https://doi.org/10.1016/j.idc.2015.02.008
7. Moritz ED, Winton CS, Johnson ST, et al. Investigational testing for Babesia microti in a repository of blood donor samples from nonendemic and endemic US regions. Transfusion. 2016;56:1berkshire–1831. PMID: 27223475. https://doi.org/10.1111/trf.13635
8. Kletsova EA, Spitzer ED, Fries BC, Marcos LA. Babesiosis in Long Island: review of 62 cases focusing on treatment with azithromycin and atovaquone. Ann Clin Microbiol Antimicrob. 2017;16:26. PMID: 28359288. https://doi.org/10.1186/s12941-017-0199-9
9. Ngo V, Civen R. Babesiosis acquired through blood transfusion, California, USA. Emerg Infect Dis. 2009;15:785–787. PMID: 19402967. https://doi.org/10.3201/eid1505.081248
10. Bloch EM, Lee TH, Krause PJ, et al. Development of a murine model for assessment of Babesia microti pathogenesis and evaluation of blood safety. Blood. 2012;119:3584–3589. PMID: 22378843. https://doi.org/10.1182/blood-2011-12-395871
11. Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review. JAMA. 2016;315:1767–1777. PMID: 27115378. https://doi.org/10.1001/jama.2016.2884
12. Weiss LM. Babesiosis in humans: a treatment review. Expert Opin Pharmacother. 2002;3:1109–1115. PMID: 12186619. https://doi.org/10.1517/14656566.3.8.1109

Back to Table of Contents

Research Papers

The following PubMed topic searches retrieve current peer-reviewed literature on Babesiosis.

1. Babesiosis Babesia microti treatment
2. Babesia intraerythrocytic pathophysiology
3. Babesiosis atovaquone azithromycin
4. Babesia transfusion transmitted
5. Babesiosis asplenic severe disease
6. Babesia Maltese cross tetrad blood smear
7. Babesiosis Lyme disease co-infection
8. Babesia exchange transfusion severe
9. Babesia PCR diagnosis sensitivity
10. Babesiosis immunocompromised relapsing
11. Ixodes scapularis Babesia tick prevention
12. Babesiosis hemolytic anemia thrombocytopenia

Back to Table of Contents

Connections

• Lyme Disease
• Ehrlichiosis
• Rocky Mountain Spotted Fever
• Q Fever
• Malaria
• Infectious Disease
• Hemolytic Anemia
• Thrombocytopenia
• Acute Kidney Injury
• Complete Blood Count
• Artemisia
• Immune Boosting

Back to Table of Contents

Featured Videos